secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001140361-24-008051
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GNI Group FY2023 revenue up 49% to ¥26.0B; Gyre expects Hydronidone IND in 2024; settles litigation for $385K
--------------------------------------------------------------------------------

- GNI Group FY2023 revenue ¥26,010M (+49% YoY), operating profit ¥13,108M (+851%), net profit ¥9,504M vs loss prior year.
- Basic EPS ¥169.50; FY2024 guidance: revenue ¥39,566M (+52%), operating profit ¥16,286M.
- Gyre expects to submit Hydronidone IND in US by end of 2024; Phase 3 trial in China last patient observation in 2024.
- Gyre (as successor to Catalyst) settles shareholder litigation over business combination; pays $385K in attorneys' fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124008051/0001140361-24-008051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124008051/ef20021723_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-008051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer